SulfatinibCAS# 1308672-74-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 1308672-74-3 | SDF | Download SDF |
| PubChem ID | 52920501 | Appearance | Powder |
| Formula | C24H25ClFN5O3 | M.Wt | 485.9 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Surufatinib | ||
| Solubility | DMSO : ≥ 100 mg/mL (208.08 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide | ||
| SMILES | CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C | ||
| Standard InChIKey | TTZSNFLLYPYKIL-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Sulfatinib Dilution Calculator
Sulfatinib Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.058 mL | 10.2902 mL | 20.5804 mL | 41.1607 mL | 51.4509 mL |
| 5 mM | 0.4116 mL | 2.058 mL | 4.1161 mL | 8.2321 mL | 10.2902 mL |
| 10 mM | 0.2058 mL | 1.029 mL | 2.058 mL | 4.1161 mL | 5.1451 mL |
| 50 mM | 0.0412 mL | 0.2058 mL | 0.4116 mL | 0.8232 mL | 1.029 mL |
| 100 mM | 0.0206 mL | 0.1029 mL | 0.2058 mL | 0.4116 mL | 0.5145 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 5-Methoxysuberenone
Catalog No.:BCN3638
CAS No.:85011-58-1
- Methyl 1,6-dihydroxy-3-methylxanthone-8-carboxylate
Catalog No.:BCN7473
CAS No.:85003-85-6
- Altrenogest
Catalog No.:BCC4479
CAS No.:850-52-2
- Sudan III
Catalog No.:BCN6962
CAS No.:85-86-9
- Sudan IV；Solvent Red 24
Catalog No.:BCN8379
CAS No.:85-83-6
- 2-Benzoylbenzoic acid
Catalog No.:BCC8561
CAS No.:85-52-9
- Maohuoside B
Catalog No.:BCN8084
CAS No.:849834-04-4
- ARP 101
Catalog No.:BCC2371
CAS No.:849773-63-3
- Deapi-platycoside E
Catalog No.:BCN3320
CAS No.:849758-42-5
- Rubicordifolin
Catalog No.:BCN7154
CAS No.:849699-55-4
- Y 134
Catalog No.:BCC7451
CAS No.:849662-80-2
- SU14813 maleate
Catalog No.:BCC1973
CAS No.:849643-15-8
- Afatinib dimaleate
Catalog No.:BCC1330
CAS No.:850140-73-7
- ADL5859 HCl
Catalog No.:BCC1265
CAS No.:850173-95-4
- Shikonofuran A
Catalog No.:BCN2826
CAS No.:85022-66-8
- Cinchonain IIb
Catalog No.:BCN7738
CAS No.:85022-68-0
- Rosin
Catalog No.:BCN5969
CAS No.:85026-55-7
- Fmoc-Arg(Tos)-ol
Catalog No.:BCC2588
CAS No.:850330-29-9
- Norviburtinal
Catalog No.:BCN4399
CAS No.:85051-41-8
- Apigenin 5-O-neohesperidoside
Catalog No.:BCN6840
CAS No.:850630-40-9
- Alogliptin (SYR-322)
Catalog No.:BCC2113
CAS No.:850649-61-5
- Alogliptin Benzoate
Catalog No.:BCC1341
CAS No.:850649-62-6
- GSK269962A
Catalog No.:BCC5178
CAS No.:850664-21-0
- BX517(PDK1 inhibitor2)
Catalog No.:BCC6391
CAS No.:850717-64-5
Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study.[Pubmed:28159938]
Oncotarget. 2017 Jun 27;8(26):42076-42086.
Sulfatinib is a small molecule kinase inhibitor that targets tumor angiogenesis and immune modulation. This phase I study (NCT02133157) investigated the safety, pharmacokinetic characteristics, and preliminary anti-tumor activity of Sulfatinib in patients with advanced solid tumors. The study included a dose-escalation phase (50-350 mg/day, 28-day cycle) with a Fibonacci (3+3) design, and a tumor-specific expansion phase investigating the tumor response to treatment. Two Sulfatinib formulations were assessed: formulation 1 (5, 25, and 50 mg capsules) and formulation 2 (50 and 200 mg capsules). Seventy-seven Chinese patients received oral Sulfatinib; the maximum tolerated dose was not reached. Dose-limiting toxicities included abnormal hepatic function and coagulation tests, and upper gastrointestinal hemorrhage. The most common treatment-related adverse events were proteinuria, hypertension and diarrhea. Among 34 patients receiving Sulfatinib formulation 2, one patient with hepatocellular carcinoma and eight with neuroendocrine tumors exhibited a partial response; 15 had stable disease. The objective response rate was 26.5% (9/34) and the disease control rate was 70.6% (24/34). Pharmacokinetic, safety, and efficacy data supported continuous oral administration of Sulfatinib at 300 mg as the recommended phase II dose. Sulfatinib exhibited an acceptable safety profile and encouraging antitumor activity in patients with advanced solid tumors, particularly neuroendocrine tumors.
